Grünenthal, a leading pharmaceutical company specializing in pain research and management, has announced significant investments in its Latin American production sites. The company has invested over €80 million to enhance its production capabilities in the region, reaffirming its commitment to long-term competitiveness and ensuring a reliable supply of medicines for patients globally.
The investments include a complete refurbishment of a 3,500-square-meter solids plant in Santiago de Chile, creating a world-class manufacturing facility with a production capacity of 1.8 billion tablets annually. In addition, a new 1,800-square-meter plant in Quito, Ecuador, will enable the production of 300 million high-quality tablets annually for pain patients in 17 European countries.
Grünenthal operates a robust production network with five manufacturing sites in Germany, Switzerland, Italy, Chile, and Ecuador. These sites not only produce medicine from Grünenthal’s portfolio but also offer contract manufacturing services to third parties. To ensure production excellence and expand the geographical reach of its Latin American facilities, Grünenthal is implementing a standardized approach to product robustness, quality, and regulatory compliance across all its global manufacturing sites.
“Our investment in Latin America is a strong demonstration of our commitment to long-term competitiveness in the region,” says Victor Barbosa, Head of Global Operations and member of the Executive Board Team. “Future-proofing our manufacturing capabilities underscores our commitment to ensuring a safe, reliable, and efficient supply of medicine to patients globally. Grünenthal delivers high-quality medicine from Latin America to the world—a unique capability in the region.“
Grünenthal has been operating in Santiago de Chile for 45 years, and the company’s largest manufacturing investment in the past three decades, a new 3,500-square-meter facility, will enable a production capacity of up to 1.8 billion tablets annually. The state-of-the-art technology will also provide training and specialization opportunities for employees, positioning them at the forefront of the industry. Grünenthal aims to complete the certification process with the European Medicines Agency (EMA) by November 2025, enabling the supply of medicines from Chile to Europe.
The company’s manufacturing site in Quito, Ecuador, is one of the few in Latin America licensed to export to Europe and the only one in Ecuador with an EU Good Manufacturing Practice certificate, setting a high industry standard. The 50,000-square-meter campus is Ecuador’s largest and most modern manufacturing plant for solid, semi-solid, and liquid pharmaceuticals. Starting in 2025, the new facility will produce up to 300 million high-quality tablets annually for pain patients in 17 European countries.
Grünenthal, headquartered in Aachen, Germany, has affiliates in 27 countries across Europe, Latin America, and the U.S., and its products are available in approximately 100 countries. In 2023, the company employed around 4,400 people and achieved revenues of €1.8 billion.
For more information about Grünenthal and its mission to change lives for the better, please visit https://www.grunenthal.com. Follow Grünenthal on LinkedIn and Instagram for updates on the company’s latest developments.
Media Contact:
Jessica Liu, Global Corporate Affairs & Communication
Email: jessica.liu@grunenthal.com
For press releases and news distribution services, please visit https://pressat.co.uk/.
